

Hear from David Blakey, Chief Scientist at AstraZeneca at RNA Therapeutics 2015

SMI's 6th annual RNA Therapeutics conference takes place on the 16th – 17th February 2015 in London, UK.

LONDON, ENGLAND, UNITED KINGDOM, December 10, 2014 /EINPresswire.com/ -- Next generation ASO technology is on track to become a key therapeutic modality to modulate intractable oncology targets, according to clinical data to be presented at the 6th annual RNA Therapeutics [conference](#).

Hear more from David Blakey, Chief Scientist at AstraZeneca in a keynote presentation entitled: Tackling Intractable targets in oncology – progress towards viable therapeutic oligonucleotides platforms. David Blackey, who has over 25 years' experience in oncology drug discover, will be explaining how ASO chemistries have limited robust activity in tumors, demonstrating robust target knock down in multiple preclinical cancer models including primary tumour explants and human tumour xenografts.

This [event](#) will provide an opportunity for attendees to research better delivery systems, look to maximise return on investment, develop RNA therapeutics for rare diseases and protect biotech innovation. Furthermore, [RNA Therapeutics 2015](#) will draw from expert opinions, showcase the latest technology and inform delegates of new strategies and best practice in clearing the path to market from cell to sales.

Key Speakers will Include:

- Claude Paul Malvy, Professor, Universite Paris Sud
- Joerg Kaufmann, Chief Scientific Officer, Silence Therapeutics
- Bo Rode Hansen, VP, Drug Discovery & Alliance, Roche
- Rodger Novak, CEO, CRISPR Therapeutics
- Annemieke Aartsma-Rus, Associate Professor, Leiden University Medical Center
- Nagy Habib, Chairman and Co Founder, MiNa Therapeutics
- David Blakey, Chief Scientist, AstraZeneca



For more information visit <http://www.smi-online.co.uk/goto/2015rna57.asp>

RNA Therapeutics

16 – 17 February 2015

Marriott Regents Park Hotel, London UK

<http://www.smi-online.co.uk/goto/2015rna.asp>

--- End ---

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries.

We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries. More information can be found at <http://www.smi-online.co.uk>

Teri Arri

SMi Group Ltd

+44 (0) 20 7827 6162

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/239060839>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.